Detoxification using nanoparticles
The present invention relates treatments of a toxin in a subject. The toxin at least partially effects its toxicity in the subject via binding to a target cell of the subject. The present invention provides for methods, combinations and pharmaceutical compositions for decreasing or neutralizing the effect of a toxin in a subject, using, inter alia, an effective amount of a nanoparticle comprising an inner core comprising a non-cellular material, and an outer surface comprising a cellular membrane derived from a source cell. Exemplary toxins include acetylcholinesterase (AChE) inhibitors such as organophosphate poisoning.
1. A method for decreasing or neutralizing the effect of a toxin in a subject, which method comprises administering, to a subject in need, or to cells of said subject, an effective amount of a nanoparticle comprising a) an inner core comprising a non-cellular material, and b) an outer surface comprising a plasma membrane derived from a source red blood cell, wherein said toxin is dichlorvos (DDVP).
2. The method of claim 1 , which is used for decreasing the effect of a toxin in a subject.
3. The method of claim 1 , wherein the inner core comprises a polymeric particle core.
4. The method of claim 1 , wherein the inner core comprises a biocompatible or a synthetic material selected from the group consisting of poly(lactic-c-glycolic acid) (PLGA), polylactic acid (PLA), polyglycolic acid (PGA), polycaprolactone (PCL), polylysine, and polyglutamic acid.
5. The method of claim 1 , wherein the inner core supports the outer surface.
6. The method of claim 1 , wherein the nanoparticle further comprises a releasable cargo.
7. The method of claim 1 , wherein the nanoparticle substantially lacks constituents of the source red blood cell that are not plasma membrane of the source red blood cell.
8. The method of claim 1 , wherein the nanoparticle substantially maintains natural structural integrity or activity of the plasma membrane derived from the source red blood cell.
9. The method of claim 1 , wherein the nanoparticle is biocompatible or biodegradable.
10. The method of claim 1 , wherein the inner core of the nanoparticle comprises PLGA.
11. The method of claim 1 , wherein the nanoparticle substantially lacks immunogenicity to the subject.
12. The method of claim 11 , wherein the red blood cell plasma membrane is derived from a source red blood cell from the same species as the subject.
13. The method of claim 1 , wherein the toxin binds to a target cell of the subject and to the source red blood cell via the same mechanism.
14. The method of claim 1 , wherein the toxin binds to a target cell of the subject and the source red blood cell via different mechanisms.
15. The method of claim 1 , which further comprises assessing efficacy of the nanoparticle and/or the another active ingredient in decreasing or neutralizing the effect of a toxin in the subject.
16. The method of claim 1 , which is used to decrease or neutralize the effect of the toxin in a subject by at least 10% compared to a comparable untreated subject or to the same subject at an untreated stage.
17. The method of claim 1 , wherein red blood cell acetylcholinesterase activity in the treated subject returns to normal after treatment.